Olive Leaf Extract and Potassium: What This BP Trial Proved

A promising blood-pressure result with an unanswered question

Olive leaf extract may modestly lower blood pressure in people with elevated readings. A new double-blind trial adds an intriguing number: after 12 weeks, participants taking olive leaf extract plus potassium had a 5.4 mmHg greater reduction in morning systolic blood pressure measured at home than those taking placebo. That is large enough to matter if it is real and durable.

But the same trial did not find a significant between-group difference in office blood pressure. Both groups improved over time. The discrepancy does not erase the home-monitoring result, but it prevents a simple conclusion that the supplement lowered blood pressure across measurement methods. It also raises a more basic problem: because the study tested olive leaf extract and potassium together, it cannot tell us which ingredient—if either—produced the result.

That design choice matters because olive leaf extract already has human trial evidence, while potassium has a long blood-pressure literature at much higher doses than the one used here. A two-ingredient product can make a tidy label. It makes a messy experiment.

What the 12-week trial found

Fladerer-Grollitsch et al.'s 2026 randomized, double-blind, placebo-controlled trial enrolled 70 adults with untreated mild-to-moderate hypertension, roughly 35 per group. For 12 weeks, the active group received 1,000 mg per day of olive leaf extract standardized to provide at least 160 mg oleuropein, plus 300 mg per day of potassium. The comparison group received placebo.

The headline outcome came from seven days of home monitoring: morning systolic blood pressure fell 5.4 mmHg more in the active group. The publication describes that result as statistically significant, but the available abstract does not report a confidence interval. Without one, readers cannot see the range of effects compatible with the data—from a small change to a materially useful one.

Office blood pressure tells a less decisive story. It declined significantly over time in both groups, with no reported significant separation between the supplement and placebo groups. Home readings can be clinically useful, and office readings have their own limitations. Still, when two measurement approaches point in different directions, the appropriate response is caution, not a stronger headline.

The trial also reported changes in cholesterol, triglycerides, insulin, oxidized LDL, high-sensitivity C-reactive protein, glucose, HbA1c, and quality of life. Total cholesterol fell by 11.1 mg/dL, LDL cholesterol by 6.9 mg/dL, and triglycerides were also reported to fall. These were secondary outcomes, and the study did not correct for multiple comparisons. A statistically positive result among many tested biomarkers can arise by chance, especially in a small trial. The lipid findings also appeared at week 6, leaving persistence through week 12 unclear.

The combination trial cannot identify the active ingredient

To test whether potassium adds to olive leaf extract, researchers need four groups: olive leaf extract alone, potassium alone, the combination, and placebo. This study had only the combination and placebo. Its home blood-pressure result could reflect olive leaf extract, potassium, an interaction between them, or ordinary variation amplified by a small sample.

The most plausible candidate is olive leaf extract, but plausibility is not proof. A systematic review and meta-analysis by Ismail et al. synthesized randomized trials of olive leaf extract alone in adults with prehypertension or hypertension and found human trial evidence consistent with blood-pressure lowering. The information available here does not provide the pooled effect estimate, so it would be wrong to claim that the new 5.4 mmHg result matches, exceeds, or falls short of the monotherapy average.

A contemporaneous double-blind, placebo-controlled trial by Lauwers et al. also tested polyphenol-rich olive extracts and cardiovascular markers in adults. It adds to the human literature on olive-derived products, but it does not solve the attribution problem in the olive-leaf-plus-potassium trial. Neither study design can establish whether 300 mg of potassium improves the effect of olive leaf extract.

Why the potassium dose deserves skepticism

Potassium can lower blood pressure, especially when it replaces sodium-rich foods or changes the dietary sodium-to-potassium balance. A 2021 systematic review and meta-analysis by Ndanuko et al. linked a higher urinary sodium-to-potassium ratio with higher blood pressure in adults. That evidence concerns diet-level exposure, not a 300 mg potassium supplement taken in isolation.

The difference is substantial. The U.S. dietary reference intake is 4,700 mg of potassium per day; 300 mg is about 6% of that amount. Trials of salt substitutes generally raise potassium intake by gram-level amounts while lowering sodium exposure. In a 2022 systematic review and meta-analysis of 23 randomized trials involving 32,073 participants, salt substitutes reduced systolic blood pressure by 4.80 mmHg (95% confidence interval, 6.12 to 3.48 mmHg lower).

That does not prove that 300 mg of supplemental potassium has no effect. It does mean the salt-substitute findings cannot justify crediting such a small dose for a 5.4 mmHg home systolic result. The study needed a potassium-only group to answer that question.

Rodent cardioprotection is a starting point, not a verdict

The interest in olive leaf extract did not appear from nowhere. A 2022 systematic review of rodent studies by Menezes et al. found that oral oleuropein and olive leaf extract produced cardioprotective effects across endpoints that included blood pressure, cardiac remodeling, and oxidative-stress markers. Those findings support biological plausibility.

They do not establish a dose, clinical effect, or cardiovascular outcome in humans. Rodents do not have to live with the same diets, comorbidities, medications, adherence problems, or blood-pressure measurement noise as people. The useful translational question is narrower: do randomized human studies show a repeatable blood-pressure effect? The olive leaf extract meta-analysis suggests the answer may be yes. The new combination study neither confirms a durable effect across measurement methods nor shows that potassium contributed.

How much weight should this study carry?

With about 35 participants per arm, the trial offers limited precision. A sample this size can produce a positive finding that overestimates the true effect, and it can miss a genuine effect in another endpoint. The unavailable confidence interval around the 5.4 mmHg estimate makes the uncertainty harder to judge.

The endpoint issue also matters. The trial reports a significant home morning systolic result but no significant between-group difference in office blood pressure. The publication does not provide enough information here to establish whether the home endpoint was prespecified or selected after reviewing the data. Either way, the disagreement should temper confidence.

Twelve weeks is enough to test a short-term blood-pressure signal. It cannot establish long-term adherence, sustained benefit, or fewer heart attacks, strokes, or deaths. Blood pressure is an important surrogate outcome, but a lower reading is not itself evidence of fewer cardiovascular events.

What to do with olive leaf extract now

Olive leaf extract has a reasonable case as a low-risk adjunct for adults with prehypertension or hypertension who want a plant-derived option and are already working on proven care. Its human evidence comes from olive leaf extract itself, not from the claim that 300 mg of potassium strengthens it. Anyone using it should discuss it with a clinician when they take blood-pressure medication, have kidney disease, or use drugs that affect potassium levels.

For blood-pressure control, the stronger foundations remain measured lifestyle and medical care: reducing excess sodium, improving dietary potassium when medically appropriate, exercising, and using prescribed treatment when needed. Dietary nitrate also has randomized-trial support; a 2025 dose-response meta-analysis of 75 randomized trials found that higher nitrate doses were associated with lower systolic blood pressure.

The fair conclusion is modest: olive leaf extract merits further study and may help some people, but this 70-person combination trial does not show that its potassium ingredient adds benefit. A larger, preregistered factorial trial using olive leaf extract alone, potassium alone, the combination, and placebo would answer the question this study leaves open.